Skip to main content
Erschienen in: Journal of Genetic Counseling 4/2014

01.08.2014 | NEXT GENERATION GENETIC COUNSELING

The Evolution of Cancer Risk Assessment in the Era of Next Generation Sequencing

verfasst von: Heather Fecteau, Kristen J. Vogel, Kristen Hanson, Shannon Morrill-Cornelius

Erschienen in: Journal of Genetic Counseling | Ausgabe 4/2014

Einloggen, um Zugang zu erhalten

Abstract

Cancer genetics professionals face a new opportunity and challenge in adapting to the availability of cancer genetic testing panels, now available as a result of Next Generation Sequencing (NGS) technology. While cancer panels have been available for over a year, we believe that there is not yet enough data to create practice guidelines. Despite this, a year of experience allows us to provide our opinion on points to consider as cancer genetic counselors incorporate this testing technology into genetic counseling practice models. NGS technology offers the ability to potentially diagnose hereditary cancer syndromes more efficiently by testing many genes at once for a fraction of what it would cost to test each gene individually. However, there are limitations and additional risks to consider with these tests. Obtaining informed consent for concurrent testing of multiple genes requires that genetics professionals modify their discussions with patients regarding the potential cancer risks and the associated implications to medical management. We propose dividing the genes on each panel into categories that vary by degree of cancer risk (e.g. penetrance of the syndrome) and availability of management guidelines, with the aim to improve patient understanding of the range of information that can come from this testing. The increased risk for identifying variants of uncertain significance (VUS) when testing many genes at once must be discussed with patients. Pretest genetic counseling must also include the possibility to receive unexpected results as well as the potential to receive a result in the absence of related medical management guidelines. It is also important to consider whether a single gene test remains the best testing option for some patients. As panels expand, it is important that documentation reflects exactly which genes have been analyzed for each patient. While this technology holds the promise of more efficient diagnosis for many of our patients, it also comes with new challenges that we must recognize and address.
Literatur
Zurück zum Zitat Ackerman, M. J., Priori, S. G., Willems, S., Berul, C., Brugada, R., Calkins, H., et al. (2011). HRS/EHRA expert consensus statement on the state of genetic testing for the channelopathies and cardiomyopathies this document was developed as a partnership between the Heart Rhythm Society (HRS) and the European Heart Rhythm Association (EHRA). Heart Rhythm, 8(8), 1308–1339. doi:https://doi.org/10.1016/j.hrthm.2011.05.020.PubMedCrossRef Ackerman, M. J., Priori, S. G., Willems, S., Berul, C., Brugada, R., Calkins, H., et al. (2011). HRS/EHRA expert consensus statement on the state of genetic testing for the channelopathies and cardiomyopathies this document was developed as a partnership between the Heart Rhythm Society (HRS) and the European Heart Rhythm Association (EHRA). Heart Rhythm, 8(8), 1308–1339. doi:https://​doi.​org/​10.​1016/​j.​hrthm.​2011.​05.​020.PubMedCrossRef
Zurück zum Zitat Kleihues, P., Schauble, B., Zur Hausen, A., Esteve, J., & Ohgaki, H. (1997). Tumors associated with p53 germline mutations: a synopsis of 91 families. The American Journal of Pathology, 150(1), 1–13.PubMedPubMedCentral Kleihues, P., Schauble, B., Zur Hausen, A., Esteve, J., & Ohgaki, H. (1997). Tumors associated with p53 germline mutations: a synopsis of 91 families. The American Journal of Pathology, 150(1), 1–13.PubMedPubMedCentral
Zurück zum Zitat Li, F. P., Fraumeni, J. F., Jr., Mulvihill, J. J., Blattner, W. A., Dreyfus, M. G., Tucker, M. A., et al. (1988). A cancer family syndrome in twenty-four kindreds. Cancer Research, 48(18), 5358–5362.PubMed Li, F. P., Fraumeni, J. F., Jr., Mulvihill, J. J., Blattner, W. A., Dreyfus, M. G., Tucker, M. A., et al. (1988). A cancer family syndrome in twenty-four kindreds. Cancer Research, 48(18), 5358–5362.PubMed
Zurück zum Zitat Meldrum, C., Doyle, M. A., & Tothill, R. W. (2011). Next-generation sequencing for cancer diagnostics: a practical perspective. Clinical Biochemistry Reviews, 32(4), 177–195. Meldrum, C., Doyle, M. A., & Tothill, R. W. (2011). Next-generation sequencing for cancer diagnostics: a practical perspective. Clinical Biochemistry Reviews, 32(4), 177–195.
Zurück zum Zitat Nichols, K. E., Malkin, D., Garber, J. E., Fraumeni, J. F., Jr., & Li, F. P. (2001). Germ-line p53 mutations predispose to a wide spectrum of early-onset cancers. Cancer Epidemiology, Biomarkers and Prevention, 10(2), 83–87.PubMed Nichols, K. E., Malkin, D., Garber, J. E., Fraumeni, J. F., Jr., & Li, F. P. (2001). Germ-line p53 mutations predispose to a wide spectrum of early-onset cancers. Cancer Epidemiology, Biomarkers and Prevention, 10(2), 83–87.PubMed
Zurück zum Zitat Pletcher, B. A., Toriello, H. V., Noblin, S. J., Seaver, L. H., Driscool, D. A., Bennett, R. L., et al. (2007). Indications for genetic referral: a guide for health care professionals. Genetics in Medicine, 9(6), 385–389.PubMedPubMedCentralCrossRef Pletcher, B. A., Toriello, H. V., Noblin, S. J., Seaver, L. H., Driscool, D. A., Bennett, R. L., et al. (2007). Indications for genetic referral: a guide for health care professionals. Genetics in Medicine, 9(6), 385–389.PubMedPubMedCentralCrossRef
Zurück zum Zitat U.S. Preventive Services Task Force (2014). Assessing the genetic risk for BRCA-related breast or ovarian cancer in women: Recommendations From the U.S. Preventive Services Task Force. Annals of Internal Medicine 160 (4), I-16-16. U.S. Preventive Services Task Force (2014). Assessing the genetic risk for BRCA-related breast or ovarian cancer in women: Recommendations From the U.S. Preventive Services Task Force. Annals of Internal Medicine 160 (4), I-16-16.
Zurück zum Zitat Robson, M. E., Storm, C. D., Weitzel, J., Wollins, D. S., & Offit, K. (2010). American society of clinical oncology policy statement update: Genetic and genomic testing for cancer susceptibility. Journal of Clinical Oncology, 28(5), 893–901.PubMedCrossRef Robson, M. E., Storm, C. D., Weitzel, J., Wollins, D. S., & Offit, K. (2010). American society of clinical oncology policy statement update: Genetic and genomic testing for cancer susceptibility. Journal of Clinical Oncology, 28(5), 893–901.PubMedCrossRef
Zurück zum Zitat Seal, S., Thompson, D., Renwick, A., Elliott, A., Kelly, P., Barfoot, R., et al. (2006). Truncating mutations in the Fanconi anemia J gene BRIP1 are low-penetrance breast cancer susceptibility alleles. Nature Genetics, 38(11), 1239–1241. doi:https://doi.org/10.1038/ng1902.PubMedCrossRef Seal, S., Thompson, D., Renwick, A., Elliott, A., Kelly, P., Barfoot, R., et al. (2006). Truncating mutations in the Fanconi anemia J gene BRIP1 are low-penetrance breast cancer susceptibility alleles. Nature Genetics, 38(11), 1239–1241. doi:https://​doi.​org/​10.​1038/​ng1902.PubMedCrossRef
Zurück zum Zitat Walsh, T., Casadei, S., Lee, M. K., Pennil, C. C., Nord, A. S., Thornton, A. M., et al. (2011). Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing. Proceedings of the National Academy of Sciences of the United States of America, 108(44), 18032–18037. doi:https://doi.org/10.1073/pnas.1115052108.PubMedPubMedCentralCrossRef Walsh, T., Casadei, S., Lee, M. K., Pennil, C. C., Nord, A. S., Thornton, A. M., et al. (2011). Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing. Proceedings of the National Academy of Sciences of the United States of America, 108(44), 18032–18037. doi:https://​doi.​org/​10.​1073/​pnas.​1115052108.PubMedPubMedCentralCrossRef
Metadaten
Titel
The Evolution of Cancer Risk Assessment in the Era of Next Generation Sequencing
verfasst von
Heather Fecteau
Kristen J. Vogel
Kristen Hanson
Shannon Morrill-Cornelius
Publikationsdatum
01.08.2014
Verlag
Springer US
Erschienen in
Journal of Genetic Counseling / Ausgabe 4/2014
Print ISSN: 1059-7700
Elektronische ISSN: 1573-3599
DOI
https://doi.org/10.1007/s10897-014-9714-7

Weitere Artikel der Ausgabe 4/2014

Journal of Genetic Counseling 4/2014 Zur Ausgabe

Update Gynäkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.